1 Japan Small Animal Medical Center, Tokorozawa-shi, Saitama, Japan 2 Laboratory of Veterinary Pathology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan 3 Kataoka Aiken Animal Hospital, Saitama, Japan and 10.4 mm × 6.1 mm, respectively). Endoscopic examination revealed partial circumferential narrowing of the transverse colon and friable colonic mucosa with multiple haemorrhagic regions ( Figure 2 ). The mucosa of the duodenum and jejunum was mildly oedematous. The thickness of the oesophageal and gastric mucosa was within normal limits. Mucosal tissue specimens were obtained from the stomach, duodenum and colon. The collected tissue samples were fixed in 10% buffered formalin and subjected to histopathological examination.
Histological examination with haematoxylin and eosin staining (HE) revealed marked ulceration of the colonic mucosa; marked alteration in the normal glandular architecture was observed in the lamina propria ( Figure  3 ). The lesions consisted of marked transmural infiltration of foamy macrophages accompanied by neutrophils, plasma cells and lymphocytes ( Figure 4) . Apart from the colonic lesion, marked infestation of mucosa spirochetes was observed in the stomach. Duodenal lesions were unremarkable. A provisional diagnosis of granulomatous colitis (GC) was made based on the histopathological appearance (HE) at day 7.
Owing to its rarity in cats, additional stains and immunohistochemistry were performed for definitive Following the definitive diagnosis, additional colonoscopic tissue sampling was performed for bacterial culture and sensitivity at day 28. After saline wash, a homogenised sample was subjected to bacterial culture. Attempts to isolate bacteria on culture media yielded enrofloxacin-sensitive E coli (2+). Treatment with enrofloxacin was also initiated at day 28. The animal was prescribed enrofloxacin (5 mg/kg q24h for 13 weeks), as recommended in dogs, 1 prednisolone (0.5 mg/kg q24h for 5 weeks), famotidine (1 mg/kg q24h for 2 weeks), metoclopramide (0.25 mg/kg q12h for 13 weeks) and the aforementioned probiotic half-tablet (q24h for 13 weeks). The cat more consistently produced solid or semi-formed stools once daily and its body weight increased to 4.75 kg by day 42.
The cat's body weight increased to 5.0 kg and formed solid stools twice daily by day 63. Although ultrasound examinations at day 119 showed persistent wall thickening of the ascending and transverse colon (4.6 mm), enrofloxacin was discontinued because the thickness of the right colic lymph nodes was within the normal limit. At day 207, approximately 3 months after cessation of the first course of enrofloxacin, recurrent diarrhoea was noted once every 3 days. Upon examination at day 234, the cat's body weight was found to have decreased to 4.8 kg. Ultrasonography revealed thickening of the ascending and transverse colonic wall (4.6 mm), and moderately enlarged right colic lymph nodes (8 mm). Serum biochemical tests revealed increased creatinine (3.4 mg/ dl) and urea nitrogen (34.5 mg/dl) levels. The cat was treated with enrofloxacin (5 mg/kg q24h for 15 weeks and q48h for the following 8 weeks). Faecal consistency dramatically improved by day 244. However, the cat experienced another episode of diarrhoea at day 751, approximately 12 months after cessation of the second course of enrofloxacin. Enrofloxacin was reinitiated (5 mg/kg q24h for 4 weeks) and a positive clinical response was noted by day 755.
The cat has been free of clinical signs for the following 7 months and has been off enrofloxacin without recurrence for 5 months (day 950). Enrofloxacin-associated retinal degeneration was not observed in the current case.
Discussion
An enteropathy called GC, or histiocytic ulcerative colitis, is characterised by granulomatous inflammation of the colonic mucosa, lamina propria and submucosa, with marked transmural infiltration of PAS-positive macrophages. 2, 3 PAS-positive material is considered to be glycoprotein from bacterial cell walls. 4 GC has been frequently reported in dogs; however, only a limited number of cases have been reported in cats. 4 Clinical presentation, and macroscopic and microscopic findings in the present study were consistent with those described in dogs. 2, 3, 5 In canine cases, macrophage heterogeneity suggests a difference in function compared with healthy individuals. 6 Although the pathogenesis is not well understood, recent studies have identified E coli in canine patients. 5, 7, 8 There are phylogenetic similarities between the E coli strain obtained from Boxer dog GC, and adherent and invasive E coli (AIEC) in human Crohn's disease. 8 AIEC is able to replicate within epithelial cells and macrophages without inducing host cell death. 9 AIEC has been isolated from the feline intestine at an exceptionally high frequency (82%), 10 and the association between AIEC and feline GC needs to be further investigated. In the current case, identification of E coli in the granulomatous lesion was consistent with a previous feline study that reported bacilli within the phagocytic vacuoles of macrophages. 4 Although not performed in the current case study, identification of the E coli strain and repeated histopathological evaluation would be valuable to understanding the nature of feline GC.
As demonstrated in canine case studies, 11 regression of clinical signs following antibacterial treatment in the present case suggests a critical role of E coli in feline GC. The cat responded well to intermittently administered enrofloxacin when it had semi-formed stools or diarrhoea.
Dramatic improvement in faecal consistency was noted within 2 weeks of antibacterial treatment, which is consistent with previous investigations involving dogs. 1 In dogs, at least 6-8 weeks of treatment at doses of 5-10 mg/kg body weight q24h is recommended. 1 However, response to antibacterials varies among individual dogs, 1, 11 and it appears that antibacterial resistance significantly affects clinical outcomes. 12 Although the current single case was insufficient to determine the factors affecting clinical outcomes in cats, a future case series would help in determining the optimal use of antibacterials in feline GC.
Over-representation of the Boxer dog breed suggests that GC might be a breed-specific disease; however, it has also been reported in other canine breeds. 2, 5, 7, [13] [14] [15] [16] While dogs <4 years of age are typically affected by GC, 2 in this case and the other case study middle-aged cats were affected. 4 The rarity of the disease in cats may suggest variation in hereditary susceptibility to E coli-related GC between dogs and cats.
The present case report described the case of a cat with E coli-related GC that regressed following longterm treatment with enrofloxacin. Clinical presentation, and endoscopic and microscopic findings closely resembled those described in dogs. Immunohistochemically, E coli was detected within granulomatous lesions, and resolution of gastrointestinal clinical signs following antibacterial treatment may reflect the critical role of E coli in feline GC. The rarity of the disease in cats may suggest substantial differences in host susceptibility to E coli-induced GC. Together with our findings, additional cases will enable a better understanding of the clinical nature of GC in cats.
Conclusions
GC should be included in the differential diagnoses in feline cases with marked submucosal infiltration of macrophages in the colon that respond poorly to immunosuppressive and dietary treatment. In such cases, further immunohistochemical identification of E coli and treatment with enrofloxacin may be suggested.
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